San Francisco, 4 February 2019: The Report Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By
Application (Brain Tumor, Blood, Breast, Ovarian, Lung Cancer), By Technology
(Cleavable, Non-cleavable Linker), And Segment Forecasts, 2019 - 2025
The global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025,
according to a new report by Grand View Research, Inc. it is projected to
expand at a CAGR of 25.9% over the forecast period. Increasing incidence of
cancer coupled with growing geriatric population are likely to drive the market
for Antibody-Drug Conjugates (ADC). Furthermore, major technological
advancements are also contributing to drive the growth. According to the World
Health Organization (WHO), the number of people aged 65 years and above, is projected
to reach 16% of the total population by 2050 from 7% in 2000. Aging has become
a substantial risk factor for numerous diseases including cancer and others.
Hence, the growing geriatric population is expected to drive growth of the
market over the forecast period.
Until 2018, four ADCs were available in the
market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate
targeting and improved technology, ADCs have been gaining a lot of attention
from both small and large pharmaceutical companies. Currently there are more
than 50 ADCs in clinical trials and it has been projected that during the
forecast period three to four ADCs will be commercialized in the area of
refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast
cancer, and ovarian cancer. It has been observed that the maximum number of
clinical trials are being conducted for lymphoma.
Seattle Genetics and Roche are leading the antibody drug
conjugate market in terms of market share. Until 2017 only two ADCs were
commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche.
Recently, two more Pfizer’s products were approved to be marketed for acute
myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been
estimated that over the forecast period, Pfizer is anticipated to gain a
significant market share.
Access Research Report of Antibody Drug Conjugate Market @ www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market
Further key findings from the report suggest:
· Breast cancer was the largest segment in
2017 and is likely to witness a significant growth over the forecast period due
to the factors such as availability of Kadcyla and high prevalence of breast
cancer
· Cleavable linker is expected to witness the
fastest growth over the forecast period as the maximum product in the pipeline
contains cleavable linkers. In addition, in 2017 two new products-Besponsa and
Mylotarg were approved in the market
· In 2017, North America was the largest
revenue generating region in the antibody-drug conjugates market. It is the
most well-established regions in terms of patient awareness and usage of ADCs
and makes up most of the existing market
· The players operating in this space are F.
Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda
Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
· Market players are adopting strategies,
such as introducing technologically advanced products, collaborations, and
geographic expansions to increase their market share. For instance, Seattle
Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris)
for refractory/relapsed Hodgkin lymphoma.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global antibody drug conjugate market on the basis of application, technology,
and region:
Antibody Drug Conjugate Application Outlook
(Revenue, USD Million, 2014 - 2025)
·
Blood Cancer
·
Breast Cancer
·
Ovarian Cancer
·
Lung Cancer
·
Brain Tumor
Antibody Drug Conjugate Technology Outlook
(Revenue, USD Million, 2014 - 2025)
·
Cleavable Linker
·
Non-cleavable Linker
Antibody Drug Conjugate Regional Outlook
(Revenue, USD Million, 2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Access Press Release of
Antibody Drug Conjugate Market@ www.grandviewresearch.com/press-release/global-antibody-drug-conjugates-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
